

Summer 2026

Dear colleague,

Update on vaccination and immunisation

We are writing to confirm the provision of routine vaccination and immunisation for patients with chronic kidney disease: [Complete routine immunisation schedule from 1 January 2026 - GOV.UK](#)

Patients with nephrotic syndrome, chronic kidney disease at stages 4 and 5 and those on kidney dialysis or with kidney transplantation should be vaccinated at time of diagnosis and then as per the Green Book vaccination schedule [Greenbook title page and index \(publishing.service.gov.uk\)](#).

SNOMED codes and GP IT systems allow the recording of the doses in electronic health records.

Patient charities have aided communication around vaccines suggested to patients and carers [Vaccines for Adults with Advanced Chronic Kidney Disease, Kidney Failure, or Kidney Transplant | National Kidney Foundation](#).
[Holiday / Travel vaccinations in transplant patients | National Kidney Federation](#)
[Shingles vaccination recommendation | Kidney Care UK](#)

Please utilise the table below to aid vaccination of your patients that fall into this high-risk group.

Autumn 2026 Updates:

Respiratory syncytial virus (RSV)

NHSE have announced that they will follow the JCVI advice that the RSV vaccine should be expanded further to include adults aged 65 to 74 years in certain clinical at-risk groups. This includes patients who are immunosuppressed. This change will happen from 1st September 2026

Pneumococcal

PCV20 is expected to replace PPV23 in adults over 65 years and the at-risk programme in late 2025/early 2026

Shingles

Individuals aged 18 years and above with severe immunosuppression (see Green Book) should be offered Shingrix[®] vaccination, as should individuals anticipating immunosuppressive therapy

Vaccine table for Renal and Transplant patients

	Glomerulonephritis on immunosuppression	CKD	Dialysis	Transplant workup	Post transplant
Influenza	Annually	Annually	Annually	Annually	Annually
Pneumococcal	Vaccine and booster every 5 years	Vaccine and booster every 5 years for patients with CKD stages 4&5	Vaccine and booster every 5 years	Vaccine and booster every 5 years	Vaccine and booster every 5 years
COVID	Augmented SARS-CoV-2 vaccine schedule, and seasonal booster doses when available	Individuals aged >75 years as per national program	Individuals aged >75 years as per national program	Augmented SARS-CoV-2 vaccine schedule, and seasonal booster doses when available	Augmented SARS-CoV-2 vaccine schedule, and seasonal booster doses when available
Hepatitis B	Hepatitis B vaccine using the high dose hepatitis B vaccine For some higher risk patients, we may suggest Hepatitis B surface antibody (HBsAb) levels checked every year, and re-vaccinate if HBsAb titres <10 mIU/mL	Should be vaccinated as soon as it is anticipated that haemodialysis or transplantation is required. CKD stage 4&5. The vaccines formulated for use in patients with chronic renal insufficiency should be used	Hepatitis B vaccine using the high dose hepatitis B vaccine Hepatitis B surface antibody (HBsAb) levels should be rechecked annually and be revaccinated if antibody titres fall below 10 mIU/mL	Hepatitis B vaccine using the high dose hepatitis B vaccine Hepatitis B surface antibody (HBsAb) levels should be rechecked annually and be revaccinated if antibody titres fall below 10 mIU/mL	Hepatitis B surface antibody (HBsAb) levels should be rechecked annually and be revaccinated if antibody titres fall below 10 mIU/mL
Respiratory syncytial virus (RSV)	Individuals aged 65 to 74 years who are immunosuppressed	Individuals aged >75 years as per national program	Individuals aged >75 years as per national program	Individuals aged 65 to 74 years who are immunosuppressed	Individuals aged 65 to 74 years who are immunosuppressed
Shingrix	Individuals aged 18 years and above with severe immunosuppression (see Green book) should be offered Shingrix® vaccination as should individuals anticipating immunosuppressive therapy	Individuals aged 18 years and above with severe immunosuppression (see Green book) should be offered Shingrix® vaccination as should individuals anticipating immunosuppressive therapy	Individuals aged >65 years as per national program	Shingrix® inactivated Varicella Zoster Virus (shingles) vaccine if 18 years of age or older	Shingrix® inactivated Varicella Zoster Virus (shingles) vaccine if 18 years of age or older
Human papillomavirus (HPV)	HPV vaccine for males and females between 9-25 years of age (using 3-dose schedule). For some higher risk patients, we may suggest HPV vaccine outside of this age range	HPV vaccine for males and females between 9-25 years of age (using 3-dose schedule). For some higher risk patients, we may suggest HPV vaccine outside of this age range	HPV vaccine for males and females between 9-25 years of age (using 3-dose schedule). For some higher risk patients, we may suggest HPV vaccine outside of this age range	HPV vaccine for males and females between 9-25 years of age (using 3-dose schedule). For some higher risk patients, we may suggest HPV vaccine outside of this age range	HPV vaccine for males and females between 9-25 years of age (using 3-dose schedule). For some higher risk patients, we may suggest HPV vaccine outside of this age range
VZV (chicken pox)				Patients who are VZV IgG negative should be vaccinated prior to transplantation. As a live attenuated vaccine, VZV vaccine should not be administered post transplant	
Measles				Patients who are measles IgG negative should be vaccinated prior to transplantation. As a live attenuated vaccine, measles vaccine should not be administered post transplant	